A client has expressive aphasia. Which part of the brain is likely affected?

Choice A rationale

This term refers specifically to the inflammation of the gallbladder wall, which is often a secondary complication of a blockage. While it is frequently caused by stones, the term itself describes the inflammatory process, which involves chemical or bacterial irritation, rather than the physical stones themselves. Patients with this condition usually present with right upper quadrant pain, fever, and leukocytosis, which are signs of an active infection or severe irritation within the biliary system.

Choice B rationale

This condition involves the presence of small, bulging pouches or sacs in the lining of the digestive tract, most commonly found in the sigmoid colon. It is related to high pressure within the colon and is entirely unrelated to the biliary system or the formation of stones in the gallbladder. This condition is often asymptomatic unless the pouches become inflamed, at which point it transitions into a different clinical diagnosis involving the lower gastrointestinal tract.

Choice C rationale

This is the specific medical term for the formation or presence of calculi within the gallbladder. These stones are typically composed of cholesterol or bilirubin that has precipitated out of the bile solution. The process occurs when bile becomes supersaturated or when the gallbladder does not empty properly. It is the correct term for the physical masses themselves, which can range in size from small grains of sand to large objects the size of a golf ball.

Choice D rationale

This term describes the infection or inflammation of the small pouches that can form in the intestines. While it shares the suffix for inflammation with Choice A, it is localized to the bowel and does not involve the gallbladder or the formation of gallstones. Symptoms usually include left lower quadrant pain and changes in bowel habits. It represents a pathological state of the intestinal wall rather than the presence of solid calculi in the biliary tree.

Choice A rationale

Acetylcholine is an excitatory neurotransmitter in the basal ganglia. In Parkinson's disease, there is a relative overactivity of acetylcholine because there is not enough dopamine to inhibit it. While the imbalance between acetylcholine and dopamine is crucial to the disease's symptoms, the primary disruption and the root cause of the pathology is the loss of dopamine. Anticholinergic medications are sometimes used to restore balance, but they do not address the primary neurochemical deficit.

Choice B rationale

Parkinson's disease is directly caused by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Dopamine is essential for the smooth, coordinated regulation of muscle movement via the basal ganglia. When dopamine levels fall by approximately 60 to 80 percent, the classic motor symptoms emerge. Most pharmacological treatments, such as Levodopa, aim to increase dopamine levels or mimic its action at the receptor site to alleviate bradykinesia, tremors, and muscle rigidity.

Choice C rationale

Serotonin is involved in mood, sleep, and appetite regulation. While patients with Parkinson's disease often suffer from depression and sleep disturbances due to secondary changes in serotonergic pathways, serotonin is not the primary neurotransmitter responsible for the motor dysfunction that defines the disease. The loss of serotonin-producing neurons may occur as the disease spreads to other brain regions, but it is considered a non-motor complication rather than the central cause of the disorder's hallmark signs.

Choice D rationale

Norepinephrine is produced by neurons that are also affected in Parkinson's disease, particularly in the locus coeruleus. This loss contributes to non-motor symptoms like orthostatic hypotension and fatigue. However, the cardinal motor features like bradykinesia and rigidity are specifically linked to the dopamine deficit. While norepinephrine plays a role in the overall clinical picture of autonomic dysfunction in Parkinson's, it is not the primary neurotransmitter whose disruption characterizes the core movement disorder.